Comparative Study between Gemcitabine Plus Cisplatin and Docetaxel Plus Fluorouracil Plus Cisplatin as Induction Chemotherapy in Unresectable Locally Advanced Head and Neck Cancer Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202406479424515

Enrollment

Registered

2024-06-28

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

fluorouracil plus docetaxel plus cisplatin

gemcitabine plus cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult patients (aged between 25- 75 years old). 2) Patients pathologically confirmed to have malignant head and neck cancer. 3) Patients with locally advanced irresectable disease. 4) Patients who had complete clinical data and follow up results 5) patients didn't receive either chemotherapy or radiotherapy before

Exclusion criteria

Exclusion criteria: 1) Patients with performance status (ECOG >2) 2) patients with distant metastatic disease. 3) patients with chronic renal disease. 4) patients with moderate to severe hearing loss

Design outcomes

Primary

Measure	Time frame
Comparison of the efficacy between gemcitabine plus cisplatin and fluorouracil plus docetaxel plus cisplatin as induction chemotherapy in unresectable locally advanced head and neck cancer patients	—

Secondary

Measure	Time frame
Evaluation of tolerability and toxicity between 2 regimen ( gemcitabine plus cisplatin) and (fluorouracil plus docetaxel plus cisplatin )as induction chemotherapy in unresectable locally advanced head and neck cancer patients	—

Countries

Egypt

Contacts

Public ContactHaytham Shaheen

Lecturer of Clinical Oncology and Nuclear Medicine suez canal university

dr.haythamshaheen@gmail.com447778070031

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026